Antibody-siRNA Conjugation (ARC)
Cell-Selective siRNA DeliverySite-Controlled AOC DesignAntibody-siRNA Conjugation for Research & Preclinical Programs
Advance targeted RNA delivery with custom antibody-siRNA conjugation services designed for discovery teams, translational researchers, and preclinical development groups. Antibody-siRNA conjugates, often discussed within the broader antibody-oligonucleotide conjugate (AOC) category, combine the target recognition of antibodies with the gene-silencing function of siRNA to help move beyond the limitations of free siRNA in cell selectivity, uptake, and tissue-directed exposure.
Our antibody-siRNA conjugation workflows are built around the variables that matter most in real projects: antibody format and receptor internalization behavior, siRNA chemistry and strand engineering, linker selection, conjugation site control, oligonucleotide-to-antibody ratio (OAR), and orthogonal analytical confirmation. For teams evaluating related formats, our capabilities can also be integrated with antibody oligonucleotide conjugation, antibody-RNA conjugation, and broader oligonucleotide bioconjugation strategies.
What Antibody-siRNA Conjugation Solves in Targeted RNA Delivery
Antibody-siRNA conjugation is used when a project needs more than sequence potency alone. Free siRNA may show strong knockdown in transfection-driven assays yet underperform once target-cell specificity, receptor-mediated uptake, endosomal trafficking, and extracellular stability become limiting factors. By covalently coupling a selected siRNA to an antibody or antibody fragment that recognizes an internalizing surface target, researchers can build a more directed delivery construct for cell-associated uptake studies, extrahepatic delivery screening, and mechanism-focused candidate comparison.
In practice, the value of an ARC program is not simply "attaching siRNA to an antibody." It lies in choosing a conjugation architecture that preserves antibody binding, keeps the siRNA functional after modification, controls heterogeneity, and produces a construct that can be purified and characterized with enough rigor to support decision-making. This is why ARC development typically requires coordinated design across protein chemistry, siRNA modification, linker engineering, and analytical validation rather than a single coupling step.
Fig 1. Antibody directly conjugated to siRNA (Paunovska, 2022)Key Challenges in Antibody-siRNA Conjugate Development
Poor Balance Between Targeting and siRNA Function
A construct may bind the intended receptor yet lose silencing efficiency if the siRNA handle, conjugation position, or linker architecture interferes with duplex behavior, intracellular release, or RISC loading. Effective ARC design must preserve both the binding function of the antibody and the biological performance of the siRNA.
Heterogeneous OAR and Conjugation Site Distribution
Random modification of lysines or partially reduced disulfides can create mixed populations with variable oligonucleotide loading. This complicates interpretation of uptake, potency, and stability data. Projects often require tighter control over conjugation site and OAR to improve comparability between batches and constructs.
Loss of Antibody Integrity During Conjugation
Over-reduction, suboptimal reaction pH, incompatible solvents, or aggressive purification conditions can damage the antibody, alter binding, or increase aggregation. ARC workflows must be tuned around protein stability as carefully as around oligonucleotide coupling efficiency.
Incomplete Analytical Visibility of the Final Construct
ARC development requires more than a pass/fail confirmation of coupling. Teams usually need clarity on free siRNA, unconjugated antibody, aggregate content, OAR distribution, identity, and sometimes site localization. Without orthogonal characterization, it is difficult to rank constructs or troubleshoot activity gaps.
Our Antibody-siRNA Conjugation Services
We provide research and preclinical antibody-siRNA conjugation support covering construct design, conjugation execution, purification, and characterization. Projects can be tailored for full-length antibodies, fragments, and selected targeting scaffolds, with chemistry choices aligned to receptor biology, payload handling, and downstream assay needs. Where homogeneity is a priority, project planning can also be aligned with principles used in site-specific antibody conjugation.
ARC Feasibility Assessment & Construct Architecture Design
Capabilities include:
- Review of target receptor biology, internalization behavior, and suitability for antibody-mediated siRNA delivery
- Selection of antibody format, including IgG, Fab, or other project-appropriate binding scaffolds
- Recommendation of siRNA attachment strand, terminal handle placement, and initial OAR target window
- Early risk mapping for steric hindrance, aggregation tendency, and payload release hypothesis
- Strategy comparison against related antibody oligonucleotide conjugation formats
Typical value:
Helps teams avoid investing in a coupling route that looks chemically feasible but is poorly matched to receptor trafficking or siRNA biology
Antibody Activation, Site Control & Conjugation Execution
Capabilities include:
- Cysteine-, lysine-, glycan-, or handle-enabled conjugation route selection based on antibody structure and desired heterogeneity profile
- Use of maleimide, click-compatible, and other covalent coupling schemes as appropriate to project design
- Control of reduction level, reactive-site exposure, and reaction stoichiometry
- Process tuning to reduce aggregation and preserve antibody binding performance
- Integration with broader protein conjugation services when additional protein-side engineering is required
Typical value:
Generates antibody-siRNA constructs with better consistency and clearer structure-function interpretation than one-step random coupling alone
siRNA Modification, Linker Engineering & Payload Optimization
Capabilities include:
- Preparation of conjugation-ready siRNA with terminal handles positioned on the selected strand
- Evaluation of linker length, polarity, and cleavable versus non-cleavable behavior
- Consideration of 2'-modification patterns, phosphorothioate placement, and duplex integrity after payload derivatization
- Optional integration with siRNA labeling for uptake tracking or assay-readout workflows
- Cross-comparison with alternative delivery concepts such as GalNAc-siRNA conjugation when project scope includes benchmark formats
Typical value:
Supports a better balance between siRNA stability, conjugation compatibility, and downstream silencing performance
Purification, Orthogonal Characterization & Batch Preparation
Capabilities include:
- Separation of target ARC from free siRNA, unconjugated antibody, and high-molecular-weight species
- Identity and integrity assessment by HPLC/UPLC, LC-MS, gel-based methods, or other fit-for-purpose analyses
- OAR estimation and comparison across batches or construct variants
- Evaluation of aggregation, fragmentation, and payload retention under defined conditions
- Reporting package with chromatograms, spectra, batch summary, and construct-specific observations
Deliverables:
Purified conjugate material plus analytical documentation suitable for construct ranking, assay transfer, and preclinical study support
Antibody-siRNA Conjugate Design Parameter Comparison
Successful antibody-siRNA conjugate development depends on coordinated control of the targeting antibody, siRNA payload, conjugation site, linker behavior, and oligonucleotide-to-antibody ratio. The table below highlights the design parameters most commonly evaluated during feasibility assessment and construct optimization.
| Design Parameter | Typical Options | Why It Matters | Main Risk if Poorly Matched | What Clients Usually Need to Confirm |
| Antibody Format | Full-length IgG, Fab, scFv, or other targeting scaffold | Influences receptor binding, internalization behavior, circulation properties, and steric accessibility for payload attachment | A format that binds well but internalizes poorly may limit productive siRNA delivery | Whether the chosen antibody format is suitable for the intended target cell uptake model |
| Target Receptor Selection | Internalizing cell-surface receptors with target-cell selectivity | Determines whether antibody binding can be translated into receptor-mediated uptake | High binding without efficient trafficking may lead to weak intracellular payload delivery | Receptor expression level, internalization rate, and relevance to the biological model |
| Conjugation Site on Antibody | Lysine residues, interchain cysteines, glycans, or engineered handles | Affects heterogeneity, antibody integrity, and preservation of binding activity | Random or poorly controlled attachment can broaden OAR distribution and increase variability | Site accessibility, structural tolerance, and reproducibility of conjugation |
| siRNA Handle Placement | 5′ or 3′ terminal modification on sense or antisense strand, depending on design strategy | Determines coupling compatibility while influencing duplex behavior and downstream silencing function | Poor handle placement may interfere with duplex stability or RISC-associated activity | Which strand and terminus can be modified with minimal impact on function |
| siRNA Chemical Modification | 2′-O-methyl, 2′-fluoro, phosphorothioate-containing regions, and other stabilization patterns | Helps balance nuclease resistance, manufacturability, and post-conjugation performance | Inadequate stabilization may reduce robustness, while over-modification may affect activity | Whether the payload remains stable and functionally compatible after conjugation |
| Linker Type | Non-cleavable, condition-sensitive, reducible, or enzyme-responsive linkers | Influences serum stability, intracellular release concept, and overall construct behavior | An unsuitable linker can weaken payload retention or reduce productive intracellular release | Whether the linker supports the intended trafficking and payload presentation strategy |
| Oligonucleotide-to-Antibody Ratio (OAR) | Low-, medium-, or higher-loading constructs depending on project goals | Balances payload density with antibody stability, aggregation risk, and interpretability | Excessive loading can damage antibody quality and complicate analytical and biological comparison | Average OAR, OAR distribution, and relationship to binding and functional readouts |
Comparison of Antibody-siRNA Conjugation Strategies
Different conjugation routes offer different trade-offs in site control, construct heterogeneity, scalability, and suitability for research-stage or optimization-stage antibody-siRNA programs. The table below summarizes commonly used strategy types and their practical selection logic.
| Conjugation Strategy | Typical Technical Approach | Advantages | Limitations | Best-Fit Use Cases |
| Lysine-Based Conjugation | Reactive groups on the antibody surface lysines are used to attach linker-bearing siRNA intermediates | Broadly accessible, relatively fast to implement, and useful for early feasibility studies | Often produces heterogeneous attachment patterns and broader OAR distributions | Rapid proof-of-concept work when strict site control is not the first priority |
| Cysteine-Based Conjugation | Controlled reduction exposes thiols for maleimide or other thiol-reactive coupling chemistry | More controlled than random lysine coupling and widely used in antibody conjugation workflows | Over-reduction can affect antibody structure, increase aggregation, or alter binding | Projects needing a practical balance between feasibility and improved conjugate uniformity |
| Glycan-Mediated Conjugation | Antibody glycans are selectively modified to create a more defined attachment region | Can reduce uncontrolled surface modification and preserve key protein regions | Requires suitable antibody glycosylation features and added processing complexity | Programs seeking more controlled attachment without relying solely on random residue modification |
| Site-Specific / Engineered Handle Conjugation | Defined reactive positions or engineered handles are introduced to guide payload attachment | Best control over conjugation position, narrower heterogeneity, and stronger structure-function interpretation | Requires appropriate antibody design and may add development time upstream | Optimization-stage projects where construct consistency and comparability are especially important |
| Click Chemistry-Based Conjugation | Bioorthogonal handle pairs such as azide/alkyne-type systems are used for modular attachment | Clean reaction logic, flexible payload installation, and good compatibility with staged assembly | Requires handle preinstallation and careful evaluation of handle placement on both antibody and siRNA | Modular construct screening and programs comparing multiple linker or payload variants |
| Hybrid / Modular Assembly | Antibody and siRNA components are prepared through staged intermediates before final construct assembly | Useful for rapid comparison of different payloads, handles, or linker modules | Can increase purification burden and workflow complexity if not well planned | Screening campaigns and structure-activity studies involving multiple ARC variants |
Analytical Characterization and QC Items for Antibody-siRNA Conjugates
Antibody-siRNA conjugates require analytical characterization beyond simple coupling confirmation. A useful QC package should help teams determine whether the final construct is sufficiently defined for uptake studies, knockdown assays, and comparative development work.
| QC / Analytical Item | Representative Methods | Purpose | What It Helps Reveal | Typical Deliverable |
| Construct Identity Confirmation | LC-MS, intact mass analysis, or other fit-for-purpose orthogonal methods | Confirms successful formation of the intended antibody-siRNA conjugate | Whether the expected payload installation has occurred at the construct level | Identity summary and molecular-weight confirmation data |
| Purity Assessment | HPLC/UPLC, electrophoretic methods, or complementary chromatographic workflows | Measures overall sample quality and separation from process-related impurities | Presence of unconjugated species, incomplete reaction products, or mixed populations | Purity profile and chromatographic or gel-based records |
| Free siRNA and Unconjugated Antibody Analysis | Orthogonal chromatographic and electrophoretic methods | Determines how much unbound payload or starting antibody remains after purification | Whether assay results could be confounded by residual free species | Free-species assessment summary |
| OAR Evaluation | Mass-based analysis, chromatographic profiling, or equivalent loading assessment methods | Estimates the amount of siRNA attached per antibody population | Whether payload loading is within the intended design range and how broad the distribution is | Average OAR estimate and comparative batch data |
| Aggregation and Fragmentation Monitoring | SEC or other aggregation-sensitive analytical workflows | Assesses whether conjugation or handling affects antibody structural quality | Formation of high-molecular-weight species or breakdown products | Aggregate/fragment profile and chromatographic overlays |
| Binding Retention Check | ELISA, SPR, cell-binding assays, or other target engagement methods | Confirms that antibody targeting performance is retained after conjugation | Whether the construct still recognizes the intended target efficiently | Binding comparison between starting antibody and final conjugate |
| Conjugation Site Investigation | Peptide mapping, subunit analysis, or targeted LC-MS workflows when needed | Provides deeper insight into where the siRNA payload is attached | Whether the conjugation pattern matches the intended site-control strategy | Site-localization or site-distribution report |
| Stability Assessment | Defined storage-condition testing, serum-exposure review, and repeat analytical measurement | Evaluates construct robustness during handling, storage, and pre-assay preparation | Payload retention, degradation trends, and handling-sensitive instability | Stability summary with time-point comparison data |
Workflow for Custom Antibody-siRNA Conjugation Projects
Project Scoping & Reagent Review
We begin by reviewing the antibody, target biology, siRNA sequence status, intended cell model, and analytical expectations. This stage defines whether the project should prioritize fast feasibility, reduced heterogeneity, or deeper structure-function comparison.
Construct Design & Chemistry Selection
The conjugation route, attachment site logic, siRNA handle placement, and linker concept are selected based on the target receptor, antibody format, and downstream use case. If needed, we also align the design with broader siRNA delivery methods benchmarking.
Antibody Activation & Payload Preparation
Antibody-side activation and siRNA-side derivatization are performed under conditions chosen to preserve protein quality and payload integrity. This is the stage where many ARC risks are controlled before the final coupling reaction begins.
Conjugation, Cleanup & Enrichment
The conjugation reaction is executed, followed by purification to remove residual free species and enrich the target construct population. Cleanup strategy is matched to the specific heterogeneity profile of the project rather than applied as a generic step.
Orthogonal Characterization & Batch Comparison
The purified ARC is characterized for identity, purity, loading, and stability-relevant attributes. Where multiple variants are prepared, comparative analysis is used to support construct ranking and help explain biological differences between candidates.
Delivery of Material & Technical Reporting
Final deliverables include conjugated material, analytical summaries, and project observations relevant to the chosen format. This helps research teams move directly into uptake studies, knockdown assays, or next-round design refinement.
Why Teams Choose Our Antibody-siRNA Conjugation Support
Design Decisions Built Around Both Protein and siRNA Constraints
ARC projects fail when antibody chemistry and oligonucleotide chemistry are treated independently. Our workflows are structured to evaluate the interface between the two, including handle placement, linker burden, steric effects, and post-conjugation function.
Better Control of Heterogeneity and OAR Interpretation
We focus on the variables that most strongly affect homogeneity, including reduction level, site accessibility, reaction stoichiometry, and purification logic. This makes it easier to compare constructs instead of testing poorly defined mixtures.
Analytical Readiness for Real Go / No-Go Decisions
ARC characterization should help explain results, not merely confirm that a reaction occurred. We emphasize orthogonal QC outputs that can support uptake studies, knockdown interpretation, and next-round optimization.
Flexible Support Across Feasibility, Optimization, and Batch Preparation
Some programs need only a few construct variants for early feasibility, while others need a more reproducible route for downstream studies. We adapt the scope to the actual stage of the project rather than forcing every program into the same package.
Application Areas of Antibody-siRNA Conjugation
Oncology Research
- Targeted delivery of siRNA to tumor-associated cell-surface markers for cell-selective gene silencing studies.
- Evaluation of receptor-mediated uptake strategies in cancer cell models with defined antigen expression.
- Support for target validation and pathway interrogation in oncology discovery programs.
Immunology and Inflammation Research
- Antibody-guided siRNA delivery to immune cell subsets involved in inflammatory signaling pathways.
- Functional investigation of cytokine regulation, receptor signaling, and immune-cell-specific gene expression.
- Useful for studying selective knockdown strategies in complex immune microenvironments.
Fibrosis and Tissue Remodeling Studies
- Targeted silencing of genes associated with fibroblast activation, extracellular matrix remodeling, and profibrotic signaling.
- Exploration of receptor-directed siRNA delivery in stromal or mesenchymal cell populations.
- Support for mechanism-focused studies in tissue remodeling and fibrosis-related research models.
Cell-Selective Functional Genomics
- Enables gene knockdown studies in defined receptor-positive cell populations without relying solely on non-targeted transfection systems.
- Useful for validating intracellular pathways in hard-to-transfect or mixed-cell systems.
- Supports comparison of targeting ligands, receptors, and intracellular delivery hypotheses in discovery research.
Extrahepatic Targeted siRNA Delivery Research
- Evaluation of antibody-mediated delivery strategies for tissues and cell types not readily addressed by ligand-based liver targeting systems.
- Comparative assessment of receptor-directed uptake across non-hepatic biological settings.
- Useful for early-stage platform exploration when selective extrahepatic delivery is a key project goal.
Target Validation and Mechanism-of-Action Studies
- Supports selective silencing of candidate genes to confirm target relevance in receptor-defined cell populations.
- Helps distinguish whether observed biological effects depend on delivery selectivity, payload activity, or receptor biology.
- Valuable for lead prioritization before broader delivery or conjugation optimization work.
Move Your Antibody-siRNA Conjugation Project Forward with a More Structured ARC Workflow
Whether you are evaluating a first antibody-siRNA construct, troubleshooting heterogeneity in an existing ARC, or building a cleaner analytical package before biological testing, we provide project-specific support across design, conjugation, purification, and characterization.
Our team works with antibody and oligonucleotide inputs in a coordinated way so that conjugation chemistry serves the biology instead of obscuring it. From feasibility studies to optimized research batches, we help generate ARC materials that are easier to interpret and more useful for downstream decision-making. Contact our scientific team to discuss your antibody-siRNA conjugation requirements, target format, and preferred analytical scope.
Frequently Asked Questions (FAQ)
What is antibody-siRNA conjugation, and how does it work?
Antibody-siRNA conjugation (ARC) is a process that involves attaching small interfering RNA (siRNA) molecules to antibodies. This conjugation enables targeted delivery of siRNA to specific cells or tissues. The antibody recognizes a particular target molecule, while the siRNA can inhibit gene expression, allowing for precise control over gene silencing in molecular studies.
How are antibody-siRNA conjugates synthesized?
Antibody-siRNA conjugates are synthesized using various conjugation methods, including thiol-maleimide coupling, amine-reactive linkers, and click chemistry. These techniques allow for stable and efficient attachment of siRNA to the antibody, ensuring that both components retain their bioactivity and targeting capabilities.
